-52.1%
TSLL vs MRNA
+52.8%
-105.0%
-82.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +10.9% | +5.8% | +5.1% | +10.1% |
| 7D | -14.3% | +21.8% | -36.1% | -16.6% |
| 30D | -6.2% | +19.6% | -25.7% | -8.5% |
| 3M | +21.2% | +354.6% | -333.4% | -13.4% |
| 6M | -36.6% | +394.9% | -431.5% | -56.6% |
| YTD | -47.8% | +812.2% | -859.9% | -71.0% |
| 1Y | -45.2% | +996.2% | -1,041.4% | -71.6% |
| 3Y | -3.3% | +287.0% | -290.2% | -37.6% |
| All | -52.1% | +52.8% | -105.0% | -59.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling